Celator Shines At ASCO, Highlights Upside For Jazz
This article was originally published in The Pink Sheet Daily
With proof of concept for its CombiPlex platform in the form of Phase III results for Vyxeos in acute myeloid leukemia, the $1.5bn purchase price paid by Jazz bought more than a promising late-stage asset.
You may also be interested in...
FDA's Office of Prescription Drug Promotion issues only its third letter of 2016, although it hopes to cast wide net by targeting high-profile events like ASCO.
Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.